MetaCap

Arcturus Therapeutics (ARCT) vs Immuneering (IMRX)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

Arcturus Therapeutics (ARCT) has outperformed Immuneering (IMRX) over the past year, gaining 19.0% versus a loss of 53.7%. Over five years, ARCT leads with a -81.3% price change compared with -85.0% for IMRX. Immuneering is the larger company by market cap ($218.9 million vs $214.7 million), about 1.0 times the size.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

ARCT+19.01%IMRX-53.70%
+182%+58%-65%
Nov 21, 20251 yearNov 20, 2026
ARCT-79.56%IMRX-86.40%
+35%-33%-102%
Nov 15, 20215 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

ARCT versus IMRX key metrics
MetricARCTIMRX
Share price$7.45$3.38
Market cap$214.73M$218.90M
1-day change-1.97%-2.03%
YTD return+21.53%-48.63%
1-year return+19.01%-53.70%
5-year return-81.32%-85.00%
EPS (TTM)$-3.10$-0.92
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Revenue (latest FY)$82.03M—
Revenue growth (YoY)-46.14%—
Net income (latest FY)$-65.78M$-56.02M
Operating margin-92.96%—
Net margin-80.19%—
52-week high$17.96$8.48
52-week low$5.50$3.29
Distance from 52-week high-58.52%-60.14%
Analyst consensusstrong_buystrong_buy
Avg. price target upside+218.12%+402.96%
Average volume851.45K747.66K
Shares outstanding28.82M64.76M
Employees10665
SectorHealth CareHealth Care
IndustryBiotechnology: Pharmaceutical PreparationsBiotechnology: Pharmaceutical Preparations

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

Key differences

  • ARCT has outperformed IMRX by 72.7 percentage points over the past year.

About Arcturus Therapeutics

ARCT stock →

Arcturus Therapeutics Holdings Inc., a messenger RNA medicines company, focuses on the development of liver and respiratory rare disease therapeutics. Its technology platforms include STARR, a self-amplifying mRNA technology platform, and LUNAR, a lipid-mediated delivery system.

Health Care · Biotechnology: Pharmaceutical Preparations · 106 employees

About Immuneering

IMRX stock →

Immuneering Corporation, a late-stage oncology company, develops medicines for broad populations of cancer patients in the United States. The company develops IMM-1-104 (atebimetinib), a dual-MEK inhibitor that is in a Phase 3 clinical trial to treat patients with cancer, including pancreatic and non-small cell lung cancer caused by mutations of RAS or RAF; IMM-6-415 (envometinib), which is in Phase 1/2a clinical trial for the treatment of patients with solid tumors; and multiple deep cyclic inhibitor discovery programs.

Health Care · Biotechnology: Pharmaceutical Preparations · 65 employees

ARCT vs IMRX FAQ

Which is bigger, Arcturus Therapeutics or Immuneering?

Immuneering (IMRX) is larger, with a market capitalization of $218.90M compared with $214.73M for Arcturus Therapeutics (ARCT).

Which stock has performed better over the past year, ARCT or IMRX?

ARCT returned +19.01% over the past 12 months, compared with -53.70% for IMRX (price return, excluding dividends). Past performance does not predict future results.

Are Arcturus Therapeutics and Immuneering in the same industry?

Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.

More comparisons